Skip to main content
VKTX logo

Viking Therapeutics, Inc.

VKTXNASDAQHealthcareBiotechnology

$27.37Today:- (-)1Y −21.19%

As of Oct 15, 2026 close

Market cap
$3.18B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$25.28$43.15
Volume (live)
-
Avg. volume (3M)
7.17M

Viking Therapeutics (VKTX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Viking Therapeutics used $278.69M of cash in operating activities. Free cash flow was −$278.69M.

Viking Therapeutics Cash Flow Statement Analysis

Values in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Viking Therapeutics, Inc. (VKTX) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-0.36-0.11-0.09-0.07-0.05-0.04-0.03-0.02-0.02
Depreciation & Amortization0.000.000.000.000.000.000.000.000.00
Deferred Income Tax0.000.000.000.000.000.000.000.000.00
Stock Based Compensation0.040.030.020.010.010.000.000.000.00
Change in Working Capital0.050.010.000.010.000.010.000.000.00
Change in Accounts Receivable0.010.000.000.000.000.000.000.000.00
Change in Accounts Payable0.040.000.000.010.000.000.000.000.00
Change in Other Working Capital0.000.000.000.000.000.01-0.010.000.00
Other Operating Activities0.000.000.000.000.000.010.000.000.00
Net Cash from Operating Activities-0.28-0.09-0.07-0.05-0.05-0.02-0.02-0.02-0.01
Investing Activities
Purchases of Investments-0.42-1.11-0.48-0.12-0.17-0.28-0.36-0.35-0.02
Sales/Maturities of Investments0.760.560.300.180.210.320.370.080.02
Other Investing Activities0.000.000.000.000.000.000.000.000.00
Net Cash from Investing Activities0.34-0.55-0.180.050.040.040.01-0.270.00
Financing Activities
Debt Repayment0.000.000.000.000.000.000.000.000.00
Common Stock Issued0.080.600.270.000.010.000.000.300.02
Common Stock Repurchased0.000.00-0.01-0.010.000.000.000.000.00
Other Financing Activities0.070.00-0.010.010.000.000.000.010.00
Net Cash from Financing Activities0.080.610.270.000.010.000.000.300.02
Summary
Effect of Forex Changes on Cash0.000.000.000.000.000.000.000.000.00
Net Change in Cash0.14-0.030.020.010.000.02-0.020.020.01
Cash at Beginning of Period0.030.060.040.030.030.010.020.010.00
Cash at End of Period0.170.030.060.040.030.030.010.020.01
Free Cash Flow-0.28-0.09-0.07-0.05-0.05-0.02-0.02-0.02-0.01

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Viking Therapeutics Cash Flow

What is Viking Therapeutics's free cash flow?

Viking Therapeutics had negative free cash flow of $278.69M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Viking Therapeutics pay dividends or buy back shares?

Viking Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition